IPCA Laboratories

IPCA Laboratories Equity

The The Equity of IPCA Laboratories (IPCALAB.NS) as of Oct 17, 2026 is 80.64 B INR. In the previous year, The Equity was 69.48 B INR — a change of 16.05% (higher).

Equity

80.64 BINR

YoY

16.05%

Last updated:

In 2026, IPCA Laboratories's equity was 80.64 B INR, a 16.05% increase from the 69.48 B INR equity in the previous year.

The IPCA Laboratories Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
31.22 B INR
Jan 1, 2020
36.27 B INR
Jan 1, 2021
47.02 B INR
Jan 1, 2022
54.65 B INR
Jan 1, 2023
58.42 B INR
Jan 1, 2024
63.32 B INR
Jan 1, 2025
69.48 B INR
Jan 1, 2026
80.64 B INR
The IPCA Laboratories Equity history
YEAREquityYoY
80.64 BINR+16.05%
69.48 BINR+9.73%
63.32 BINR+8.39%
58.42 BINR+6.90%
54.65 BINR+16.23%
47.02 BINR+29.61%
36.27 BINR+16.18%
31.22 BINR+16.14%
26.89 BINR+9.50%
24.55 BINR+8.68%
22.59 BINR+2.30%
22.08 BINR+12.69%
19.60 BINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? IPCA Laboratories Ltd, based in Mumbai, India, is a leading pharmaceutical company engaged in the manufacture, research, and development of over 350 formulations and 80 active pharmaceutical ingredients (APIs). The company operates 18 manufacturing units in India and markets its products in more than 100 countries worldwide. IPCA offers a wide range of APIs and branded pharmaceuticals, including Zerodol, Lariago, and Tenoric, covering various therapeutic areas. With 16,167 employees, it serves global markets from its headquarters in Maharashtra. IPCA Laboratories is one of the most popular companies on Eulerpool.

Equity Details

Analyzing IPCA Laboratories's Equity

IPCA Laboratories's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding IPCA Laboratories's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating IPCA Laboratories's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

IPCA Laboratories's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in IPCA Laboratories’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about IPCA Laboratories stock

The Equity of IPCA Laboratories is 80.64 B INR in 2026.

The Equity of IPCA Laboratories changed from 69.48 B INR to 80.64 B INR, representing a 16.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

The Equity's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's IPCA Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — IPCA Laboratories

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — IPCA Laboratories